| New
Treatments Chemotherapy
trials |
Radiation oncology trials | Glossary
of terms The
MGH Brain Tumor Center is dedicated to the discovery of better treatments for
patients with brain tumors. As a result, patients at the center may have the opportunity
to participate in clinical trials. To find out more about clinical trials, review
this page or call the Center at 617.724.8770.
Chemotherapy Trials The
Brain Tumor Center conducts studies of many new treatments. Some of these studies
are organized by the Center's investigators working together with pharmaceutical
companies, others are performed by consortia of research hospitals in the US and
Canada. The MGH Brain Tumor Center is a founding member of the National Cancer
Institute-sponsored cooperative clinical trials group called New Approaches to Brain Tumor Therapy (NABTT).
Current
Clinical Trials at the MGH Brain Tumor Center |
Updated 10/17/03
| |
Agent/Investigator |
Study Type |
Description |
Status |
Radiation Oncology
Trials The
MGH is a participating institution in trials sponsored by the Radiation
Therapy Oncology Group (RTOG).
Current
Clinical Trials at the MGH Brain Tumor Center | |
Agent |
Study Type |
Description |
Status |
Glossary of Terms
Some
definitions of terms used in clinical trials of new brain tumor treatments may
be helpful. Phase
I - A small trial, typically with only 10 to 12 patients, designed to test the
toxicity of increasing doses of a new agent. Phase
II - Larger trial to assess whether a agent from the Phase I level can effectively
treat a tumor. Phase
III - Very large trial designed to compare how a new agent from the Phase II level
compares to the best currently available agent(s). Neoadjuvant
- Agent is administed after biospy (or surgery), but prior to irradiation. Adjuvant-
Agent is administered after biospy (or surgery) and completion of irradiation. Recurrent
- Agent is administered at the time of tumor progression or recurrence. | 
![[Divider]](/images/barrule.gif){kind=small}
